How to develop innovative treatments for neglected diseases – presentation by Novartis
Lynne McGrath, Vice President and US DRA Head of Oncology at Novartis, presented at last year’s World Orphan Drug Congress USA on the drug Glivec, and how it was approved for not one but four orphan indications.
Though not drug repositioning in the strictest sense, could Novartis’s expertise in expanding indications for one drug be a way to streamline several uses of a molecule, incorporating “drug repositioning” from the early stages of clinical development?
Some of the key topics covered in her presentation include:
- Setting up NIBR regardless of market size
- Expanding application to common diseases
- Transforming a promising candidate drug into a treatment reality that benefits patients
Are you interested in ways to improve collaboration and speed-up drug repositioning so patients can get treated faster and more affordably? At this year’s World Drug Repositioning Congress USA, Pfizer, Merck, Celgene and Eli Lilly will all be presenting and sharing further insights on drug repurposing.
Valery Alakhov, Vice President of Research & Development and Chief Science Officer from Supratek Pharma will be presenting a keynote address on the topic, ‘Why oncology is the most opportunistic therapeutic field for repositioning’.